Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Findeisen, Kate E; Sewell, Julia; Östör, A.

doi:10.2147/btt.s252575

Cited by 20 publications

(17 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given safety concerns and the higher reported prevalence in our data, it is encouraged to educate patient using bDMARDs to perform frequent monitoring and assessment. This could be done through adherence to follow-up appointments ( Findeisen et al, 2021 ). Patients should also be educated on importance of proper life style and nutrition which could help reducing disease progression and could be an area for future research for its effect on prevalence of ADRs ( Gioia et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study

Almalag

AlAujan

Alhazzani

et al. 2022

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study

Almalag

AlAujan

Alhazzani

et al. 2022

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

“…A demyelinating disease of the CNS and the spinal cord is the most common neurological complication occurring during anti-TNF-alpha treatment [39]. These complications most often occur in patients who are 51 years old on average, and in women [79,80]. Typical clinical symptoms are mental confusion, paresthesia, speech impediments, cognitive impairments, and numerous impairments of motor activity (apraxia, paralysis of the limbs, or hemiparesis) [44].…”

Section: Demyelinating Diseases Of the Cns And The Spinal Cordmentioning

confidence: 99%

“…Various authors have also pointed out cases in which different methods of treating IFN-beta were used. Stopping anti-TNF-alpha therapy and using pulse MP and IVIG allows for the recovery of approximately 35-37% of patients [79,80].…”

Section: Demyelinating Diseases Of the Cns And The Spinal Cordmentioning

confidence: 99%

“…There are several possible explanations of the very frequent neurological side effects within the course of anti-TNF-alpha therapy. The first is that the decrease in the concentration of active TNF-alpha in the area of the nerve cell may lead to inhibition of the molecular cascades connected with the TNRF receptors whose stimulation is necessary for the proliferation of oligodendrocytes and remyelination [80]. The second possibility is an abnormality of the immune defense mechanism of the nerve tissue resulting from inhibition of the activity of TNF-alpha, which may lead to the activation of latent infection of the CNS [117].…”

Section: Possible Explanations Of the Mechanism Leading To Complications Including The Connection Between Psoriasis And The Nervous Systementioning

confidence: 99%

See 1 more Smart Citation

Neurological Complications of Biological Treatment of Psoriasis

Ożóg

Grabarek²,

Wierzbik-Strońska

et al. 2022

Life

View full text Add to dashboard Cite

In the available literature, little attention has been paid to the assessment of psoriasis and the biological therapy used for it and the nervous system. The purpose of this article is to discuss the relationship between psoriasis and the nervous system as well as to analyze the mechanisms that lead to neurological complications during anticytokine therapies in psoriasis. However, this connection requires further analysis. The use of biological drugs in psoriasis, although it yields positive therapeutic results, is not without numerous side effects. Serious neurological side effects of the therapy are most often visible with the use of anti-TNF-alpha, which is why patients should be monitored for their potential occurrence. Early detection of complications and rapid discontinuation of treatment with the drug may potentially increase the patient’s chances of a full recovery or improvement of his/her neurological condition. It also seems reasonable that, in the case of complications occurring during anti-TNF-alpha therapy, some of the drugs from other groups should be included in the therapy.

show abstract

“…Over the years, numerous nanobiotechnology (Bindra et al, 2021; Huang et al, 2018; Jain et al, 2021; Patel et al, 2022; Shi et al, 2017) and cellular‐based therapeutic strategies (Basar et al, 2020; Findeisen et al, 2021; Fischbach et al, 2013; Ullah et al, 2015; Yu et al, 2020) have been applied for targeted cancer therapy although the cost of treatment is rising continuously (J. Herrmann, 2020; Schmidt et al, 2020; Vokinger et al, 2020). Systemic administration and delivery of therapeutic probes viz., anticancer drugs on target site have been affected by off‐targeting that lead to design of localized therapies with low efficacy and high toxicity (Genard et al, 2017; Pich et al, 2019; Van der Jeught et al, 2018; Vokinger et al, 2020; Ward et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

Bioinspired soft nanovesicles for site‐selective cancer imaging and targeted therapies

Prasad

Conde

2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Cell-to-cell communication within the heterogeneous solid tumor environment plays a significant role in the uncontrolled metastasis of cancer. To inhibit the metastasis and growth of cancer cells, various chemically designed and biologically derived nanosized biomaterials have been applied for targeted cancer therapeutics applications. Over the years, bioinspired soft nanovesicles have gained tremendous attention for targeted cancer therapeutics due to their easy binding with tumor microenvironment, natural targeting ability, bioresponsive nature, better biocompatibility, high cargo capacity for multiple therapeutics agents, and long circulation time. These cell-derived nanovesicles guard their loaded cargo molecules from immune clearance and make them site-selective to cancer cells due to their natural binding and delivery abilities. Furthermore, bioinspired soft nanovesicles prevent cell-to-cell communication and secretion of cancer cell markers by delivering the therapeutics agents predominantly. Cell-derived vesicles, namely, exosomes, extracellular vesicles, and so forth have been recognized as versatile carriers for therapeutic biomolecules. However, low product yield, poor reproducibility, and uncontrolled particle size distribution have remained as major challenges of these soft nanovesicles. Furthermore, the surface biomarkers and molecular contents of these vesicles change with respect to the stage of disease and types. Here in this review, we have discussed numerous examples of bioinspired soft vesicles for targeted imaging and cancer therapeutic applications with their advantages and limitations. Importance of bioengineered soft nanovesicles for localized therapies with their clinical relevance has also been addressed in this article. Overall, cell-derived nanovesicles could be considered as clinically relevant platforms for cancer therapeutics.

show abstract

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Cited by 20 publications

References 73 publications

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study

Prevalence of adverse reactions to intravenously administered originator biologics in patients with rheumatoid arthritis: A 5-year retrospective study

Neurological Complications of Biological Treatment of Psoriasis

Bioinspired soft nanovesicles for site‐selective cancer imaging and targeted therapies

Contact Info

Product

Resources

About